The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test
- PMID: 36652189
- DOI: 10.1007/s13187-023-02264-1
The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test
Abstract
There is controversy on prostate cancer screening with the prostate-specific antigen (PSA) test in the USA, and as a result, there has been an increased push for physicians to have a thorough discussion with patients on the advantages and disadvantages of prostate cancer screening with the PSA blood test. Prior studies showed that pre-screening discussions increased the likelihood of PSA testing. This study is aimed at examining the impact of discussions of the advantages and disadvantages of the PSA test among men that fit the prostate cancer screening guidelines determined by the American Urological Association (AUA). This cross-sectional study used secondary data from the 2018 Behavior Risk Factor Surveillance System (BRFSS) in the USA. The analytic sample was determined based on the American Urological Association (AUA) guidelines for prostate cancer screening (n = 54,607). Approximately, 89.5% of men underwent PSA testing. The odds of PSA testing were higher for men who received information on only the advantages of PSA testing (OR = 3.40, 95% CI = 2.80, 4.13), only the disadvantages of PSA testing (OR = 1.52, 95% CI = 1.02, 2.28), and both advantages and disadvantages of PSA testing (OR = 2.99, 95% CI = 2.46, 3.63) compared to men who received no information. Discussions with men, that meet the requirements for prostate cancer screening, about the advantages and disadvantages of PSA testing increased the likelihood that men would undergo PSA testing.
Keywords: Cancer education; Prostate cancer screening; Prostate-specific antigen; Shared decision making; USA.
© 2023. The Author(s) under exclusive licence to American Association for Cancer Education.
Comment in
-
Guidelines by Urologists and Public Health Professionals: Different Perspectives on Prostate Specific Antigen Screening.J Cancer Educ. 2023 Aug;38(4):1109-1110. doi: 10.1007/s13187-023-02331-7. Epub 2023 Jun 17. J Cancer Educ. 2023. PMID: 37330457 No abstract available.
Similar articles
-
Disparities Associated with Shared Decision-making in Prostate Cancer Screening.Eur Urol Focus. 2023 Nov;9(6):1008-1015. doi: 10.1016/j.euf.2023.04.013. Epub 2023 May 15. Eur Urol Focus. 2023. PMID: 37198068
-
The State of Prescreening Discussions About Prostate-specific Antigen Testing Following Implementation of the 2012 United States Preventive Services Task Force Statement.Urology. 2017 Jun;104:122-130. doi: 10.1016/j.urology.2016.12.069. Epub 2017 Mar 16. Urology. 2017. PMID: 28322897
-
Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States.Ann Fam Med. 2018 Mar;16(2):139-144. doi: 10.1370/afm.2200. Ann Fam Med. 2018. PMID: 29531105 Free PMC article.
-
Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.J Natl Med Assoc. 2006 Apr;98(4):492-504. J Natl Med Assoc. 2006. PMID: 16623061 Free PMC article. Review.
-
Screening for prostate cancer: the current evidence and guidelines controversy.Can J Urol. 2011 Oct;18(5):5875-83. Can J Urol. 2011. PMID: 22018148 Review.
Cited by
-
Prostate Cancer Screening Decisions: Which Aspects Do Men Value Most? An Interview Study With Men Invited to a Population-Based Program.Am J Mens Health. 2025 May-Jun;19(3):15579883251344563. doi: 10.1177/15579883251344563. Epub 2025 Jun 23. Am J Mens Health. 2025. PMID: 40548674 Free PMC article.
-
Guidelines by Urologists and Public Health Professionals: Different Perspectives on Prostate Specific Antigen Screening.J Cancer Educ. 2023 Aug;38(4):1109-1110. doi: 10.1007/s13187-023-02331-7. Epub 2023 Jun 17. J Cancer Educ. 2023. PMID: 37330457 No abstract available.
References
-
- Tian J-Y, Guo F-J, Zheng G-Y, Ahmad A (2018) Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. Carcinogenesis 39:307–317. https://doi.org/10.1093/carcin/bgx141 - DOI - PubMed
-
- Schatten H (2018) Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol 1095:1–14. https://doi.org/10.1007/978-3-319-95693-0_1 - DOI - PubMed
-
- Ferlay J, Shin H-R, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. https://doi.org/10.1002/ijc.25516 - DOI - PubMed
-
- Carter HB (2013) American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int 112:543–547. https://doi.org/10.1111/bju.12318 - DOI - PubMed
-
- Carter HB, Albertsen PC, Barry MJ et al (2013) Early detection of prostate cancer: AUA Guideline. J Urol 190:419–426. https://doi.org/10.1016/j.juro.2013.04.119 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous